Join
Live feed
·
PRReleasevia Quantisnow
MetaVia Inc. logo

MetaVia Doses the First Patient in Higher-Dose Phase 1 Study of DA-1726, Its GLP-1 and Glucagon Dual Agonist for the Treatment of Obesity

ByQuantisnow·Wall Street's wire, on your screen.
MTVA· MetaVia Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track MTVA (MetaVia Inc.) and more on Quantisnow.